Shanghai Haohai Biological Technology Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Shanghai Haohai Biological Technology Co., Ltd. carries a market capitalization of 5.74B, placing it among publicly traded companies globally. Its enterprise value stands at 8.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.74B |
| Enterprise Value | 8.88B |
Valuation Ratios
Shanghai Haohai Biological Technology Co., Ltd. trades at a trailing price-to-earnings ratio of 53.19.
| PE Ratio | 53.19 |
| PS Ratio | N/A |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Shanghai Haohai Biological Technology Co., Ltd. maintains a current ratio of 7.51, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.51 |
| Quick Ratio | 5.44 |
| Debt / Equity | 14.59 |
| Debt / EBITDA | 3.84 |
| Interest Coverage | N/A |
Stock Price Statistics
Shanghai Haohai Biological Technology Co., Ltd.'s stock has declined approximately -39.84048% over the past 52 weeks. The 50-day moving average sits at 34.28, while the 200-day moving average is 43.11.
| Beta (5Y) | N/A |
| 52-Week Price Change | -39.84048% |
| 50-Day Moving Average | 34.28 |
| 200-Day Moving Average | 43.11 |
| Average Volume (20 Days) | N/A |
Margins
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Profit Margin | N/A |
| EBITDA Margin | 55.73 |
Stock Splits
Shanghai Haohai Biological Technology Co., Ltd.'s most recent stock split took place on June 20, 2024 with a 5:7 split ratio.
| Last Split Date | 6/20/2024 |
| Split Ratio | 5:7 |
Scores
Shanghai Haohai Biological Technology Co., Ltd. posts an Altman Z-Score of 3.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.13 |